Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Peter Clark, MA, MD, FRCP: A Payer Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




May
08
Today In Oncology
Bavituximab Plus Pembrolizumab for Patients With Hepatocellular Carcinoma
Effects of Radiation Therapy Timing on Lifespan of Artificial Urinary Sphincters in Prostate Cancer Survivors
Hemihepatectomy Outcomes With Laparoscopic vs Open Surgery
T-DXd vs Physicians Choice of Therapy in HER2-Positive Metastatic Breast Cancer PROs in DESTINY-Breast02
Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside